
AZ ends Calquence trial early after Phase 3 success in chronic lymphocytic leukaemia
pharmafile | May 8, 2019 | News story | Research and Development | AstraZeneca, Calquence, pharma
AstraZeneca has unveiled new Phase 3 data on the efficacy of its Bruton tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) in the treatment of previously-treated patients with chronic lymphocytic leukaemia (CLL), demonstrating that the therapy “significantly increased the time patients live without disease progression” in interim analysis.
In the study, 310 participants were randomised into two groups, with one group receiving Calquence 100mg twice daily, and the second group receiving rituximab plus either Roche’s Mabthera (idelalisib) or Gilead’s Zydelig (bendamustine).
It was found that use of Calquence as a monotherapy led to statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) compared to the regimens administered in the second group.
As a result, AZ revealed that the Phase 3 study would end early, now that the drug has proven its efficacy in meeting the trial’s primary endpoint.
“Calquence is the first BTK inhibitor to show benefit in a Phase 3 trial as a monotherapy compared to current standard-of-care combinations used in relapsed or refractory chronic lymphocytic leukaemia,” commented José Baselga, Executive Vice President, R&D Oncology at AZ. “We look forward to presenting detailed results at a forthcoming medical meeting.”
Matt Fellows
Related Content

AstraZeneca’s Trixeo approved in EU for asthma
AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved in the European Union as a …

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …






